These findings indicate that Ang-II can regulate lymphangiogenesis in LECs via AT1R, highlighting the potential of AT1R blockers to treat hypertension and associated cardiovascular remodeling by targeting RIG-I. The gene discussed is AGT; the disease is Hypertension.